Filing summary
Entity and period: The supplied filing is Diffusion Pharmaceuticals Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2018—not a filing under the name Cervomed Inc.
Business context
Diffusion is a clinical-stage biotechnology company developing trans sodium crocetinate (TSC), intended to improve oxygenation in hypoxic tumors and enhance standard cancer treatments. Its principal program is a Phase 3 trial of TSC in newly diagnosed, inoperable glioblastoma; enrollment began in January 2018. The company also described a planned Phase 2 stroke study, conditional on funding, and was exploring options for RES-529.
Financial performance and liquidity
- Revenue: No product-sale revenue; none expected in the foreseeable future.
- Operating expenses: $3.35 million, up from $2.57 million in Q1 2017. Research and development expense rose to $1.83 million from $1.01 million, primarily due to the Phase 3 GBM trial; general and administrative expense was $1.50 million, versus $1.55 million.
- Loss: Operating loss was $3.35 million, compared with $2.57 million. Net loss was $3.31 million, versus $28.64 million in Q1 2017. The prior-year loss included substantial warrant and financing charges that did not recur in 2018. Q1 2018 net loss attributable to common stockholders was $11.57 million, including an $8.17 million deemed dividend related to the preferred-stock make-whole conversion. Basic and diluted loss per share was $0.27, versus $2.78.
- Cash flow: Operating activities used $3.29 million, compared with $3.42 million. Financing activities provided $10.59 million, and cash increased by $7.30 million.
- Cash and liquidity: Cash and cash equivalents were $16.20 million at March 31, 2018, up from $8.90 million at year-end 2017. Working capital was $15.7 million. Management estimated cash would fund operations through June 2019.
- Debt: $550,000 of convertible debt was current, bears 1% interest, converts at $2.74 per share, and matures June 30, 2018. Accrued interest was approximately $39,000.
- Margins: Not meaningful because the company had no product revenue.
Material changes and financing
- In January, the company sold 15 million common shares with warrants and received approximately $10.6 million in net offering proceeds. The filing also reports differing gross-proceeds figures in different sections; see investor verification items below.
- All Series A preferred stock converted into 21.0 million common shares, including shares for accrued dividends and a make-whole adjustment. Common shares outstanding increased to 50.5 million from 14.5 million at year-end.
- There were 31.7 million common-stock warrants outstanding at quarter-end, including 17.7 million issued in the 2018 offering. Potential dilution is substantial.
- Research and development spending increased as the Phase 3 GBM trial advanced. The company expects expenses and losses to continue rising.
Outlook, risks and contingencies
- Management said cash was sufficient through June 2019, but additional financing would be needed to complete the GBM trial and pursue further development. The company had no committed credit facilities or other committed capital and warned that financing may not be available on acceptable terms.
- If funding is unavailable, the company may delay or reduce programs, seek collaborations or strategic alternatives, or cease operations. Additional equity financing could dilute shareholders.
- Nasdaq notified the company on March 2, 2018 that its share price had been below $1 for 30 consecutive business days. It had until August 29, 2018 to regain compliance by meeting the minimum bid-price test.
- A former CEO’s arbitration claim seeks damages in an undetermined amount. The company considers the matter without merit, but says it cannot predict the outcome or potential loss.
- The filing reported no material changes to previously disclosed risk factors, no material changes in internal control over financial reporting, and effective disclosure controls. No product approvals or commercial revenue were reported.
Most important facts to verify
- Confirm the intended issuer: the provided filing identifies Diffusion Pharmaceuticals Inc., not Cervomed Inc.
- Reconcile the offering proceeds: the filing describes approximately $10.8 million in one passage, approximately $12.0 million gross in another, and approximately $10.6 million net in its cash-flow discussion.
- Track available cash, quarterly operating cash use, and whether management’s June 2019 runway estimate changes as the Phase 3 trial progresses.
- Monitor the June 30, 2018 convertible-debt maturity and the Nasdaq bid-price compliance deadline.
- Assess Phase 3 enrollment and execution, future financing needs, and dilution from outstanding warrants and options.
- Follow the former CEO arbitration and any developments that could affect the company’s financial position.